e-Drug3D

1746

LENVATINIB

INN
LENVATINIB

cas 417716-92-8

CLASS

ANTINEOPLASTIC
TREATMENT OF THYROID CANCER
RECEPTOR TYROSINE KINASE (RTK) INHIBITOR
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS VEGFR1 (FLT1), VEGFR2 (KDR) AND VEGFR3 (FLT4) INHIBITOR
FIBROBLAST GROWTH FACTOR (FGF) RECEPTORS FGFR1, 2, 3, AND 4 INHIBITOR
PDGFRALPHA, KIT AND RET INHIBITOR

ROUTE (list)

ORAL

ATC code

L01EX08

PK parameters

F 85 PERCENT
Tmax 2.5 HOUR
VD 82 LITER
PPB 98.5 PERCENT
t1/2 28 HOUR

Solubility

SLIGHTLY SOLUBLE IN WATER

Target

TARGET VEGFR RECEPTORS

PDB
3WZD (KDR IN COMPLEX WITH LIGAND LENVATINIB)

Ligand code = LEV (link to the list of PDB complexes)

Download experimental 3D coordinates of LEV with added hydrogens

DrugCentral

Proto-oncogene tyrosine-protein kinase receptor Ret UNIPROT P07949 RET

Mast,stem cell growth factor receptor Kit UNIPROT P10721 KIT

Download SDF file

6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-

Formula:
C21H19ClN4O4

Calculated chemical properties:

MW 426.85
NB_atoms 30
XLogP 4.07
PSA 106.89
NB_HD 4
NB_HA 8
fsp3 0.19
Lipinski(0=no;1=yes) 1

FDA
NDA 206947 (label) INN (LENVATINIB MESYLATE) LENVIMA (EISAI INC) APPROVAL= AP YEAR= 2015
NDA 213092 (pdf not found) INN (LENVATINIB MESYLATE) LENVATINIB (SUN PHARM INDS INC) APPROVAL= TA YEAR= 2022